#USA #Minneapolis #Erectile Dysfunction #ROXUS #LTR Pharma

Introduction

LTR Pharma Limited, an Australian-based pharmaceutical company, recently announced the availability of Roxus® in the U.S., a new compounded intranasal formulation of vardenafil designed to treat erectile dysfunction (ED). This product is a significant advancement in the treatment of ED, as it provides a rapid onset of effect, reaching peak plasma levels in just ten minutes.

Rapid Access to Treatment

Accessible through Strive Pharmacy, which specializes in personalized medication, Roxus® is specifically formulated for patients who require quicker solutions compared to traditional oral PDE5 inhibitors. This unique delivery method allows users to bypass the usual concerns associated with tablet-based medications, which often require planning around meal times and sexual activities.

Clinical Insights

Clinical studies indicate that many men, approximately 30% to 35%, may not adequately respond to oral medications for ED. This situation creates a need for alternative therapies like Roxus. In early trials, intranasal vardenafil demonstrated a significant advantage over its oral counterpart, showing quicker absorption and effectiveness when administered through the nasal route. Roxus® was shown to deliver peak plasma concentrations much faster than the oral tablets, which typically take at least 30 minutes.

In fact, a Phase 1 study comparing the two forms of treatment found that while the oral tablet took about 45 minutes to peak, Roxus® achieved a similar result in only ten minutes—providing a viable solution for those seeking more spontaneity in their intimate encounters.

Real-World Effectiveness

Data collected from a cohort of men in Australia who received treatment with SPONTAN® (the precursor to Roxus) indicated promising results: 68% reported improved erectile function, while notably, 93% of men who sought a quicker option after experiencing inadequate responses to oral therapy also reported satisfaction with Roxus®. This data underscores Roxus's potential to fulfill the needs of various demographics, including older men and those with specific dietary restrictions affecting absorption rates of traditional medications.

Target Audience

Dr. Andrew Sun, a key figure at LTR Pharma, emphasizes that Roxus may particularly benefit adult men who both require PDE5 inhibitor therapy and prefer spontaneity in their sexual lives. Ideal candidates include those:

• - Struggling with oral medications due to timing with meals
• - Experiencing gastrointestinal discomfort from tablets
• - Looking for quick onset of action, especially older adults who require predictable effects.

However, it is noteworthy that patients must not have significant nasal issues that could hinder absorption.

Dosing Information

The dosing protocol for Roxus requires the patient to administer the intranasal spray approximately 10-15 minutes prior to sexual activity, with a maximum frequency of once every 24 hours. It's essential to highlight that sexual stimulation is still necessary for the medication to take effect.

Safety and Considerations

As with any medication, Roxus comes with several safety considerations: contraindications include patients taking nitrates or those with known sensitivities to vardenafil. Caution is advised for individuals with heart and liver issues, as well as those experiencing QT prolongation.

Common side effects can include headaches and nasal irritation, but the overall tolerability appears to mirror that of traditional ED treatments. Importantly, since Roxus is a compounded medication, it is tailored for individual patient needs and is not subject to the same approval process as standard pharmaceuticals by the U.S. FDA.

Closing Thoughts

With the launch of Roxus®, LTR Pharma aims to enhance the quality of life for men dealing with erectile dysfunction. By providing a quick-acting alternative, Roxus® not only represents a substantial innovation in men’s health but also redefines how intimacy may be approached in underserved patient populations. As the drug continues to undergo further clinical evaluation, its success could lead to broader applications in the realm of men’s health pharmacotherapy.

For more detailed information or assistance, healthcare providers are encouraged to reach out through official channels or visit LTR Pharma's website.